An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 55, Issue 11, 1996, Pages 833-836

  Huizinga, Tom W J ^a   Dijkmans, Ben A C ^b   Van Der Velde, Edo A ^a   Van De Pouw Kraan, Tineke C T M ^c   Verweij, Cornelis L ^a   Breedveld, Ferdinand C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029801341     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.11.833     Document Type: Article

References (14)

1. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
2. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effect of an engineered anti-TNF antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-43.
3. Han J, Thompson P, Beutler B. Dexamethasone and Pentoxifylline inhibit endotoxin-induced cachectin/TNF synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-4.
4. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, et al. Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation. Blood 1991; 78:1205-11.
5. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Favei AS, Hofman GS. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest 1994; 93:17-25.
6. Diperri G, Diperri IG, Monteiro GB, Bonora S, Hennig C, Cassatella M, et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J Infect Dis 1995;171:1317-22.
7. Maksymowych WP, Avinazubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22:625-9.
8. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
9. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
10. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
11. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-9.
12. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989;16:159-63.
13. Revuz J, Guillaume J, Janier M, Hans P, Marchand C, Souteyrand P, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990;126:923-7.
14. Chrousos GP. Seminars in medicine of the Beth Israel Hospital, Boston: the hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62.